SCHEMBL4484141

SCHEMBL4484141

CN1CCN(CC(=O)N(C)c2ccc(N/C(=C3\C(=O)Nc4cc(Cl)ccc43)c3ccc(CC(=O)O)cc3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.42
DRD4 P21917 1/20 0.41
RET P07949 2/20 0.38
NTRK1 P04629 2/20 0.38
ABL1 P00519 1/20 0.38
CSF1R P07333 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
FGFR1 P11362 1/20 0.38
PDGFRA P16234 1/20 0.38
FLT1 P17948 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR4 P22455 1/20 0.38
FGFR3 P22607 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
NTRK3 Q16288 1/20 0.38
GHSR Q92847 3/20 0.36
PIM1 P11309 2/20 0.36
PIM2 Q9P1W9 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484153 1.00 AAK1 (0.42) AAK1DRD4RETNTRK1ABL1
SCHEMBL226539 0.93 AAK1 (0.44) AAK1DRD4RETNTRK1ABL1
SCHEMBL226540 0.93 AAK1 (0.44) AAK1DRD4RETNTRK1ABL1
SCHEMBL223794 0.93 AAK1 (0.41) AAK1DRD4RETNTRK1ABL1
SCHEMBL223795 0.93 AAK1 (0.41) AAK1DRD4RETNTRK1ABL1
SCHEMBL4505332 0.92 AAK1 (0.44) AAK1DRD4RETNTRK1ABL1
SCHEMBL4505327 0.92 AAK1 (0.44) AAK1DRD4RETNTRK1ABL1
SCHEMBL226941 0.92 AAK1 (0.43) AAK1DRD4RETNTRK1ABL1
SCHEMBL226942 0.92 AAK1 (0.43) AAK1DRD4RETNTRK1ABL1
SCHEMBL4485411 0.92 AAK1 (0.46) AAK1DRD4RETNTRK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR AAK1 1080/4885DRD4 1051/4885RET 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.